Mikael Dolsten
Senior Vice President & President, BioTherapeutics Research & Development

Dr. Mikael Dolsten is the President of BioTherapeutics Research & Development, a new division within Pfizer that will drive industry leadership, expertise, and innovation in the areas of biotherapeutics and vaccines. BioTherapeutics R&D will combine nimble entrepreneurial Biotech Units with core platforms and Research units with deep disease area expertise to discover innovative therapeutic programs in biotherapeutics, vaccines, and small molecules. Industry-leading technology, clinical, biological platform disciplines in BioTherapeutics R&D will efficiently advance programs into clinical development, successful proof-of-concept studies, and eventual launch of new high impact medicines by the respective Pfizer Business Unit.

Previously, Mikael was Senior Vice President, Wyeth Inc. and President of Wyeth Research where he led a global organization of some 6,000 staff throughout the U.S., Europe and Asia, focused on the research and development of small molecules, vaccines and protein-based medicines in therapy areas including Inflammation, Women's Health, Neuroscience, Oncology, Infectious diseases (vaccines, antibiotics), Hemophilia, GI and Musculoskeletal diseases. He was also a member of the Management, Operations, Human Resources/Benefits and the Law and Regulatory Committees of Wyeth Pharmaceuticals.

Before joining Wyeth, Mikael served as Executive Vice President within Pharmaceutical Research & Development/Medicine at Boehringer Ingelheim. He was responsible for leading the company's worldwide pharmaceutical research in the U.S., Canada, Germany, Italy, Austria and Japan - with major programs in seven therapeutic areas, including respiratory, inflammation/immunology, oncology, virology, cardiovascular, metabolism and CNS. In addition, he was a member of the corporate management team responsible for reviewing all worldwide development projects and licensing opportunities.

Prior to joining Boehringer Ingelheim, Mikael spent more than 15 years in leadership roles in pharmaceutical research, including positions with AstraZeneca (Respiratory, Immunology, CV, Metabolism, GI) and Pharmacia & Upjohn (Oncology, Immunology).

Mikael earned his Ph.D. in tumor immunology and M.D. from the Medical Faculty, University of Lund in Sweden. He also studied virology and cell biology at the Weizmann Institute in Israel and has been appointed as Adjunct Professor in Immunology at the Medical Faculty in Lund.

Mikael has published several patents and approximately 150 articles in international journals.